<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306332</url>
  </required_header>
  <id_info>
    <org_study_id>PSCT10</org_study_id>
    <nct_id>NCT00306332</nct_id>
  </id_info>
  <brief_title>T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      T-cell and B-cell depletion in allogeneic peripheral blood stem cell transplantation by using&#xD;
      immunomagnetic negative and positive selection procedures&#xD;
&#xD;
      Background:&#xD;
&#xD;
      Removal of T-cells from the donor graft (T-cell depletion) offers the possibility for&#xD;
      prevention of GVHD and subsequently less transplant related morbidity and mortality after&#xD;
      allogeneic stem cell transplantation (SCT). There are several techniques to deplete T-cells&#xD;
      from the stem cell grafts e.g. physical, immunological and combined physical / immunological&#xD;
      separation methods. All these techniques result in a stem cell graft with sufficient CD34+&#xD;
      stem cells combined with an adequate depletion of T and B cells. CD34+ selected stem cell&#xD;
      grafts are very pure and do not contain any additional cell populations. In contrast,&#xD;
      CD3+/CD19+ depleted grafts still contain NK-cells, monocytes and dendritic cells that are&#xD;
      part of the innate immune system. Theoretically,the presence of these cells may positively&#xD;
      influence immunological reconstitution and the graft-versus-leukaemia (GVL) effect,&#xD;
      respectively, resulting in improved outcome after SCT&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the differences in immunological reconstitution, transplant related mortality,&#xD;
      disease-free survival and overall survival after T-cell depleted allogeneic SCT for&#xD;
      haematological malignancies using either immunomagnetic CD34+ selection or immunomagnetic&#xD;
      CD3+/CD19+ depletion using the CliniMACS system in approximately 270 consecutive patients.&#xD;
&#xD;
      Additionally in this study in 20 consecutive patients the kinetics of NK-cel reconstitution&#xD;
      and differences in NK-cell repertoire will be monitored. NK-cell mediated anti-tumor&#xD;
      reactivity will be monitored in patients transplanted with and without NK-cells in the stem&#xD;
      cell graft (CD3+/CD19+ depletion, versus CD34+ selection). Secondary objectives are to&#xD;
      evaluate the clinical relevance of minor histocompatibility-specific cytotoxic T-cell&#xD;
      responses for the GVL effect, the kinetics of NK-cell reconstitution and differences in&#xD;
      NK-cell repertoire using the different T-cell depletion protocols.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Single center prospective randomised phase III study&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Patients eligible for allogeneic SCT according to the standard criteria of our institution&#xD;
      who will receive an allogeneic T- and B-cell depleted SCT with peripheral stem cells of an&#xD;
      HLA-identical sibling donor or an HLA-identical unrelated voluntary (VUD) donor.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      T-cell depletion will be conducted using two different techniques: either immunomagnetic&#xD;
      CD34+ selection or immunomagnetic CD3+/CD19+ depletion.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoints are immunological reconstitution, relapse, disease free survival and&#xD;
      overall survival. Secondary endpoints: NK-cell reconstitution and NK-cell mediated&#xD;
      anti-tumour reactivity. Cytotoxic T-cell responses for the GVL effect.&#xD;
&#xD;
      Estimated efforts and risks for participating patients:&#xD;
&#xD;
      We don't expect any extra patient efforts or risks because T-cell depletion is a standard&#xD;
      procedure in our clinic for many years. There is extensive experience with immunological&#xD;
      T-cell depletion techniques. We hypothesize CD3+/CD19+ depletion will favour stem cell&#xD;
      transplant outcome. Immunological and molecular biological studies will be performed on blood&#xD;
      samples already obtained as part of the standard protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis has shown that the objectives of this study can not be reached&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical relevance of mHag-specific CTL responses for the GVL effect</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of NK-cel reconstitution</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in NK-cell repertoire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK cell mediated anti tumor reactivity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <condition>Leukemia, Lymphocytic</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-cell and B-cell depletion</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the diagnosis of:&#xD;
&#xD;
               -  De novo acute myeloid leukaemia in first or second remission.&#xD;
&#xD;
               -  Secondary acute myeloid leukaemia in first or second remission supervening after&#xD;
                  myelodysplastic syndrome or cytotoxic / immunosuppressive therapy.&#xD;
&#xD;
               -  Acute lymphoblastic leukaemia in first or second remission.&#xD;
&#xD;
               -  Myelodysplastic syndrome.&#xD;
&#xD;
               -  Chronic myeloid leukaemia, patients who are candidate for SCT.&#xD;
&#xD;
               -  Malignant lymphoma following relapse or first line therapy resistant.&#xD;
&#xD;
               -  Aggressive mantle cell lymphoma in first complete remission.&#xD;
&#xD;
          -  Age 18-65 years.&#xD;
&#xD;
          -  WHO performance 0-1 (see appendix ).&#xD;
&#xD;
          -  Availability of an HLA-identical sibling or HLA, A, B, DRB, DQB -identical VUD donor.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Witnessed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe cardiac dysfunction (NYHA-classification II-IV)&#xD;
&#xD;
          -  Patients with severe pulmonary dysfunction (vital capacity or diffusion &lt; 70% of&#xD;
             predicted value).&#xD;
&#xD;
          -  Patients with hepatic dysfunction, bilirubin or transaminases &gt; 2.5 x upper normal&#xD;
             limit&#xD;
&#xD;
          -  Patients with renal dysfunction, serum creatinin &gt; 150 umol/liter or clearance &lt; 40&#xD;
             ml/minute.&#xD;
&#xD;
          -  Patients with a history of moderate ore severe CNS disturbances and psychiatric&#xD;
             problems.&#xD;
&#xD;
          -  Prior treatment with chemotherapy, immunotherapy, radiation therapy or surgery within&#xD;
             the last 3 weeks before entering the study.&#xD;
&#xD;
          -  Patients with active uncontrolled infections.&#xD;
&#xD;
          -  Patients who are poor medical risks because of non malignant systemic disease.&#xD;
&#xD;
          -  Patients with severe coagulopathy.&#xD;
&#xD;
          -  Patients to be known HIV positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas Schaap, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>476 Hematology, University Medical Centre St Radboud Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Schaap N, Schattenberg A, BÃ¤r B, Preijers F, Geurts van Kessel A, van der Maazen R, de Boo T, de Witte T. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol. 1997 Sep;98(3):750-9.</citation>
    <PMID>9332335</PMID>
  </reference>
  <reference>
    <citation>Schattenberg A, Schaap N, Preijers F, van der Maazen R, de Witte T. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients. Bone Marrow Transplant. 2000 Jul;26(1):17-22.</citation>
    <PMID>10918401</PMID>
  </reference>
  <reference>
    <citation>Schaap N, Schattenberg A, BÃ¤r B, Preijers F, van de Wiel van Kemenade E, de Witte T. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia. 2001 Sep;15(9):1339-46.</citation>
    <PMID>11516094</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2006</study_first_posted>
  <last_update_submitted>August 17, 2009</last_update_submitted>
  <last_update_submitted_qc>August 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <keyword>Allogeneic Stem cell transplantation</keyword>
  <keyword>T-cell depletion</keyword>
  <keyword>B-cell depletion</keyword>
  <keyword>Immunomagnetic selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

